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1. The complex spectrum of neurodegenerative diseases
Epidemiologic data indicate that neurodegenerative diseases
(NDDs) show high prevalence with a trend of a progressively
growing incidence, especially in aging societies. This presents
an increasing social and economic burden. In individuals >60
years of age, the prevalence of Alzheimer’s disease (AD) is
estimated to be 40 of 1000 persons with an annual incidence of
34 per 1000 persons.1 Parkinson’s disease (PD) is considered
the second most common NDD after AD,2 and, similarly to AD,
its prevalence consistently increases with age.
The pathologic term neurodegeneration refers to a heteroge-
neous group of progressively evolving central nervous system
(CNS) and brain diseases. It is an “umbrella” term indicating
gradual structural neuronal loss with functional consequences
due to the abnormal accumulation of misfolded and dysfunc-
tional proteins within the complex nervous system. Therefore,
NDDs are better classified as protein misfolding disorders or
proteinopathies of the CNS and the brain. For consistency
reasons, however, we will use the traditional term of NDDs
throughout this perspective.
NDDs may be either monogenic (i.e., characterized by muta-
tions) like Huntington disease, with more-or-less monolinear
mechanistic pathophysiology, or complex polygenic (e.g., spo-
radic late-onset AD), that is, involving several pathophysiologi-
cal and nonlinear progressive biologicalmechanisms.3 Lifestyle,
environmental risk factors, and variability of individual genetic
polymorphisms contribute to the onset and progression of the
idiopathic and polygenic forms of NDDs. In this perspective, we
focus on the complexmultifactorial NDDs that aremost relevant
and represent the major clinical phenotypes, including cognitive
impairment and dementia in the general aging population.
Among emerging theories, it has been postulated that
a specific misfolded protein characteristic of the
pathobiochemistry in a particular NDD can spread from one
cell to another (both transcellularly and synaptically) in a prion-
like manner, thus potentially inducing complex neural network
alterations, which are structural and functional system sub-
strates of clinical symptomatic progression at advanced stages
of NDDs.4,5 Notably, these aberrantly altered proteins represent
candidate targets for therapy development and/or may be uti-
lized as specific diagnostic and prognostic biomarkers of
disease. The neurodegenerative process is hypothesized to ini-
tiate focally and then propagate strategically across wider brain
regions through complex networks, in line with specific
dynamic progression patterns likely defined by genetic drivers
and triggers during the initiation stages of the proteinopathy.4,6
Hence, as a consequence, the emerging pathophysiological
mechanisms, the subsequent neuropathology, and both the time
of onset and dynamics of progression through time and space
and the emergence of the late-stage clinical phenotype of NDDs
can vary substantially between postulated clinical disease
groups, subsets of disease, and individuals grouped into those
operationalized categories. For instance, “typical AD”—that is,
the hippocampal variant of AD according to the International
Working Group-2 diagnostic criteria7—shows, at the preclinical
asymptomatic stage, a marked alteration and subsequent
disruption of the default mode network,6 whereas primary
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progressive aphasia displays a pattern of network dysfunction
mainly localized in language brain areas.4 However, several
cases of amyloid beta (Aβ) pathophysiology may also exhibit
atypical patterns of network change leading to disconnection
and disintegration.7 The atypical variants—namely, frontal,
posterior, and logopenic—present behavioral, visual, or lan-
guage symptoms, which from a clinical point of view overlap
those involved in other NDDs. These include behavioral
frontotemporal dementia (FTD), generally categorized as a
tauopathy; dementia with Lewy bodies (DLB), which is
linked to synucleinopathies; and primary progressive aphasia,
classified as transactive-response DNA-binding protein 43
proteinopathy or, alternatively, as a tauopathy. As a result, dis-
tinct proteinopathies may induce different patterns of early
functional and anatomic alteration of brain networks in NDDs.
Moreover, it remains unclear how misfolded proteins are trans-
lating into distinct patterns of complex network impairment
over longer periods of years and decades and, ultimately, result
in very different clinical motor and/or cognitive syndromes.
2. An outdated vision
On this basis of an inherent genetic and biological hetero-
geneity, determination of an early and accurate diagnosis of
NDDs merely from descriptive clinical symptoms and syn-
dromes is most challenging and questionable. In the past 30
years, international diagnostic consensus criteria for diagnosing
NDDs in the clinical setting scenario have been formulated
more or less slowly, refined and updated to ameliorate the
phenotypical characterization of disease categories associated
and compared with final postmortem pathologic examination.
However, in spite of intense efforts, the clinical criteria for
diagnosing NDDs still remain largely variable in terms of delin-
eation between categories and their subsets, diagnostic and
classificatory accuracy, and clinical practicality.7–13 Postmortem
neuropathologic studies confirm that the clinical diagnostic cri-
teria of PD are very good, in terms of both sensitivity (90%) and
specificity (around 100%), at distinguishing PD from other
forms of Parkinsonism, provided that they are assessed in
expert centers highly specialized in the diagnosis of movement
disorders.10 For AD, the neuropathologic “gold standards”14
have shown that purely clinical diagnostic criteria15 exhibit cor-
relative accuracy in terms of sensitivity (81%) and specificity
(70%), mostly in specialist settings. The clinical diagnostic
criteria for other NDDs exhibit high specificity but low sensi-
tivity; in this respect, the clinical diagnostic criteria for DLB
have very good specificity (95%) but poor sensitivity (around
30%),16 although according to the third report of the DLB
Consortium,13,16 the sensitivity has recently improved. Simi-
larly, the criteria for progressive supranuclear palsy display a
specificity of 100% and a sensitivity of 50%.12 Moreover,
pathologic examination9 has shown that the accuracy of the
clinical diagnostic criteria for corticobasal degeneration, a rare
form of atypical Parkinsonism, is unsatisfactory. This applies to
the clinical diagnostic criteria of FTD11 as well; indeed, as
opposed to a specific disease category, FTD is considered a
disease spectrum in itself clinically characterized by progres-
sive behavioral, executive, and language impairment, encom-
passing symptoms typical of motor neuron diseases (i.e.,
amyotrophic lateral sclerosis), and Parkinsonism.17 Notably,
the overlapping impact of cerebrovascular alterations in
neurodegenerative processes should also be carefully consid-
ered in the clinicopathologic interpretation of any NDDs.18 In
conclusion, in most cases, a classification system based purely
on a clinical descriptive diagnosis is largely heterogeneous,
practically highly unreliable, and not very helpful as a basis of
therapy development across the NDD spectrum. The traditional
clinicopathologic diagnosis scheme is largely unable to specifi-
cally consider the diverse genetic underpinnings and multiple
pathophysiological mechanisms underlying the complex
dimensional spectrum of NDDs.
Given the substantial discrepancies commonly found between
clinical and pathologic diagnoses, the idea of an existing
biunivocal relationship between a definite clinical phenotype
and its corresponding neuropathology appears misleading and
unrealistic. In addition, proteinopathies may largely appear in
combination with effects associated with brain aging and
cerebrovascular disease, thus arranging a complex multidimen-
sional and not categorical clinicopathologic continuum exhibiting
mixed patterns of partly converging neurodegenerative mecha-
nisms with overlapping and converging comorbidities.3,7,8
Currently, based on the pathologic deposition of misfolded
proteins in the CNS, NDDs may be categorized as follows:
cerebral amyloidosis (AD), tauopathies (progressive supra-
nuclear palsy, corticobasal degeneration, behavioral variant of
FTD, progressive nonfluent aphasia of FTD), synucleinopathies
(PD, DLB, multiple system atrophy), and transactive response
DNA-binding protein 43 proteinopathies (semantic variant of
FTD, behavioral FTD, amyotrophic lateral sclerosis).5
However, postmortem neuropathologic examination fre-
quently reveals the deposition of multiple misfolded proteins,
reflecting a mixed pattern of proteinopathies in an examined
patient. DLB and PD with dementia often present overlapping
Aβ-related pathology. Several studies have reported the accu-
mulation of α-synuclein within Lewy body inclusions in the
brains of AD patients.8 In addition, minor strokes, small vessel
disease, and cerebral amyloid angiopathy, alone or in combina-
tion, are associated with high prevalence of progressive
neurodegeneration, thus making it additionally challenging to
precisely label and dissect any pathologic categorization.18 In
this regard, a community-based neuropathologic study has
reported a consistent variability in the expression of several
combinations of multiple proteinopathies within the CNS of
elderly subjects. This demonstrates that the coexistence of
mixed neuropathologies is commonly observed in the clinical
setting19 and increasingly during aging.
3. Forward an adaptive perspective
In view of this, the way forward is to expand the scope of
detection and diagnosis in defining biological criteria of NDDs,
as in other disease fields. Discovery, development, and valida-
tion of distinct biological/pathophysiological biomarkers and
genetic drivers/triggers of NDDs is the key to step up progress
of in vivo diagnostic, prognostic, and therapeutic (biomarker-
guided therapy) technologies. In particular, (1) postmortem
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examination is not sufficient or practical for early detection and
diagnosis purposes; (2) postmortem examination represents not
an early dynamic in vivo assessment but rather a late-stage
result of visible traces of several pathophysiological mecha-
nisms potentially leading to different dynamics of onset and
progression; (3) asymptomatic and cognitively healthy elderly
subjects are likely to display postmortem neuropathologic
deposits of misfolded protein; (4) multiple misfolded deposits
of proteins detected within the CNS may coexist in the same
clinical phenotype or in the same patient; (5) a clinical pheno-
type may exhibit more than 1 aberrant process of protein depo-
sition; and (6) a general agreement on the definition of
pathologic vascular processes and dementia is still missing.8,18
To overcome stagnation in effective early disease detection
and drug development for NDDs, a paradigm shift is evolving
from clinically and clinicopathologic descriptive phenotypes to
clinicobiological definitions, toward the ultimate solutions of a
true “precision medicine”.
The precision medicine paradigm aims at targeting the issue
of genetic, molecular, and clinical heterogeneity by identifying
a person’s comprehensive and specific pattern of risk, reflected
by polygenetic as well as epigenetic20 variants, such as high-to-
medium risk mutations, structural, functional, and metabolic
imaging indicators, and fluid biomarkers, then detecting and
delineating the array of molecular pathophysiological mecha-
nisms underlying disease processes and finally administering a
preventive or therapeutic intervention that is specific (i.e., “tai-
lored or customized”) to the identified molecular pattern and
biological disease progression pattern in time and space.
This paradigm is clearly in contrast with the traditional
idea that NDDs are homogeneous clinicopathologic and
clinicobiological entities and can be treated with the resulting,
largely inadequate “one-drug-fits-all” approach.21 Notably, the
scientifically advanced, more matured translational research
fields of oncology or rheumatology have already begun the
implementation and practical use of precision medicine and
could serve as an inspirational model for neuroscience, neurol-
ogy, and psychiatry. This approach is promising breakthroughs
in the future of medicine, including the almost isolated and
detached field of complex psychiatric disorders.21 Thanks to the
emergence of systems theory and the complex neural network
paradigm, the implementation of large-scale biological data-
bases, and the development of high-throughput screening
methods—the “-omic” tools—which can aid in characterizing
disease biomarkers, precision medicine is likely to be practi-
cally applied broadly across a vast number of human diseases.
Such an integrative and interdisciplinary approach is possible
through the maturing field of systems biology.22
Translating innovative concepts from theory to practice is
undoubtedly challenging, especially in the multifaceted and
still largely unexplored field of neurologic and psychiatric brain
diseases. In summary, we need an innovative, practical model
allowing patient stratification in a way that is pertinent to
clinical trials. To this end, for patients showing cognitive
impairment supposedly associated with a proteinopathy or
neurodegeneration, we propose a practical diagnostic approach
structured on 3 different assessment levels: (1) traditional, clini-
cal descriptive; (2) transitional, both clinical and biomarker
based; and (3) an unbiased biomarker-guided a posteriori
aggregation scheme. Our initial aim will be to compare the 3
levels of stratification to overcome traditional reductionistic and
obsolete classification models. The first level will be based on a
purely clinical diagnostic categorization, in which we will study
the diagnostic accuracy of core biomarkers (i.e., Aβ1–42, p-tau,
t-tau) as well as novel emerging candidate biomarkers in dis-
criminating between a priori defined clinical groups (for
instance, typical AD dementia patients vs. probable DLB
(dementia stage) patients). The second level will encompass a
combined clinical- and a biomarker-driven diagnostic
approach. In detail, we will test the performance of the array of
emerging and novel candidate biomarkers to differentiate sub-
groups of patients within the dementia and mild cognitive
impairment categories as well as in asymptomatic subjects
stratified according to the unbiased descriptive “A/T/N” system
for characterizing the AD spectrum, recently proposed by Jack
and colleagues.23 In brief, this unbiased classification scheme—
theoretically appropriate for any NDD—is based on 3 binary
biomarker categories that reflect the core pathophysiological
mechanisms of AD: in particular, “A” refers to Aβ pathology,
“T” to hyperphosphorilated tau (p-tau) pathology, and “N” to
total tau (t-tau) or other biomarkers of neurodegeneration.23 In
the third level of analysis, we will preserve the conceptual
distinction of the severity of cognitive impairment by identify-
ing 3 “macroclinical” categories of subjects/patients: (1)
asymptomatic subjects, (2) prodromal or mild cognitive impair-
ment subjects, and (3) syndromic demented patients. Succes-
sively, within these categorical diagnostic macrogroups, we will
employ advanced machine learning techniques to define novel
patient subsets in an unbiased a posteriori clustering process
based on a combination of genetic polymorphisms, blood- and
cerebrospinal fluid (CSF)-based fluid biomarkers, and
multimodal neuroimaging data. We will focus on unsupervised
pattern recognition methods with the objective of detecting
higher-order, nonlinear associations within the multidimen-
sional data point represented by each patient in the highly
heterogeneous space constituted by genetic, imaging, and
biohumoral data. This will result in novel innovative, unbiased
categorizations based on effective degrees of freedom present
in a subject’s enlarged biomarker panel, hence independent of
the large variance clinical phenotypes, and these degrees of
freedom will define and span the effective dimensions of the
biological continuum of NDDs. In turn, this could form the
basis for formulating mechanistic (rather than purely data-
driven) integrative models, with the goal of explaining disease
endophenotypes and phenotypes in an individualized fashion.24
The parameters estimated by these models could aid in early
detection, diagnosis, and prognosis and eventually function as
so-called preventive biomarkers (i.e., aid in stratifying the
population into risk classes).24 As a final result of this articu-
lated process, a set of optimal cutoffs and, hence, an unbiased
descriptive panel displaying a sequence of categorizations for
NDDs may be developed (Fig. 1).
During the past decade, conceptual shifts have occurred in
the field of NDDs, and these diseases are now considered as
385Biomarker classification of neurodegenerative diseases
partly overlapping, dynamic, nonlinear progressive “dimen-
sions” that reside among a wide spectrum of brain
proteinopathies. Future breakthrough discoveries are likely to
happen through transfertilization from more advanced research
fields, such as oncology, by means of the innovative precision
medicine and systems biology paradigms. This reintegration of
neuroscience and neurology into biological medicine will be
characterized by advancing biomarker research objectively
reflecting the multifaceted pathophysiological profile of spo-
radic and polygenic NDDs. This will allow the characterization
and identification of disease even at the earliest asymptomatic
preclinical stage through population-based screening efforts
facilitated by the Precision Medicine Initiative. In this context,
given that early biomarker-guided intervention may offer the
best chance of therapeutic success, the preclinical stage of AD
and other NDDs has become a major research focus. To date,
very little evidence has been established on this uncharted
“silent stage”.25 A clarification is needed about the definitions
and lexicon, the limits, the natural history, the markers of risk
and progression, and the ethical consequence of detecting the
disease at this asymptomatic stage and how to effectively
operationalize precision medicine.
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extrapyramidal signs, cerebellar ataxia, etc. * Evolving array of validated pathophysiological and topographic biomarkers (genetic, biochemical, neuroimaging).
A = Aβ amyloid; MCI = mild cognitive impairment; N = t-tau; S = α-synuclein; SCI = subjective cognitive impairment; T = p-tau; V = vascular.
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